StockMacro
Menu

ARCH Venture Fund IX Overage, L.P.

Entity reporting insider trades (Form 4): 10% owner CIK 1666307Its filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 16 Oct 2019, sold $40K in 1 sale and bought $33.2M in 3 open-market purchases across 4 companies.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Vir Biotechnology VIR10% owner16 Oct 201916 Oct 20191$20.0M–
Sana Biotechnology SANA10% owner8 Feb 20248 Feb 20241$10.0M–
Boundless Bio BOLD10% owner2 Apr 20241 Jul 20261$3.2M1$40K
Lyell Immunopharma LYEL10% owner6 Mar 20264 Nov 2026––

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After purchasestoo few trades3 tradestoo few trades3 tradestoo few trades3 trades
After salestoo few trades1 tradeno trade old enoughno trade old enough

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––1$40K-$40K
20242$13.2M––$13.2M
20191$20.0M––$20.0M

Every trade

6, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
4 Nov 2026Lyell Immunopharma LYELfiled jointly with 4 othersBuythe same trade was reported by another filer; counted there0Not filedNot filedNoForm 4filed 5 Nov 2026
1 Jul 2026Boundless Bio BOLDfiled jointly with 7 othersSellafter exercising options16,000$2.49$40KNoForm 4filed 6 Jul 2026
6 Mar 2026Lyell Immunopharma LYELfiled jointly with 4 othersBuythe same trade was reported by another filer; counted there0Not filedNot filedNoForm 4filed 9 Mar 2026
2 Apr 2024Boundless Bio BOLDfiled jointly with 7 othersBuy200,000$16.00$3.2MNoForm 4filed 4 Apr 2024
8 Feb 2024Sana Biotechnology SANAfiled jointly with 9 othersBuy1,818,181$5.50$10.0MNoForm 4filed 12 Feb 2024
16 Oct 2019Vir Biotechnology VIRfiled jointly with 6 othersBuy1,000,000$20.00$20.0MNot statedForm 4filed 18 Oct 2019

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.